The stocks of PFE announced their quarterly dividend report on the 22nd of April, which was then sent out to investors. Most of the shareholders have stated that they would be paid a per-share dividend of 0.39 by the company. This indicates an annualized dividend of $1.56 with a 3.95% yield rate. The biopharmaceutical company has also reduced the payment of its dividends by around 10.9% in the last couple of years.
The Quarterly Estimates Of PFE
The stocks of PFE traded on Thursday at $39.53. The market cap of the firm is $220.48 billion, with a 25.50 PE ratio, and a 2.79 PEG ratio. The moving average price of the company over 50 days is $36, with a moving average price over 200 days set at $36.66. The year low of the company is $31.61, with a year high of around $43.08. The debt-to-equity ratio of the company is 0.76, with a 1.40 current ratio, and a 1.13 quick ratio.
PFE previously reported their quarterly report on the 2nd of February. The company had reported an EPS of $0.42, which just missed out on the consensus estimate of $0.46 for this quarter. The revenue of the firm was $11.68 billion, which was more than the analyst sum of $11.32 billion. The return on equity for the company was 24.88%, with a 17.85% net margin.
The stocks of PFE have been commented upon by quite a few research equities. The Royal Bank of Canada has already put up a rating of “sector perform” along with a price target of $42 set on the stock. DZ Bank has also put up a rating of buy with a price target of $41 in a 3rd February research report. TheStreet has also reduced the rating of the company from b to c+ in a 5th March research report. JPMorgan Chase & Co has also put up a target price of $36 with a rating of neutral in a 3rd February research report.
Eleven investment analysts have already given the stocks a rating of hold, while three others have given the company a rating of buy. PFE currently has a hold rating with a price target of $38.47.
